The company tightened it FY2022 revenue guidance to be in the range of $79M - $82M, from prior outlook of $79M - $84M, but the mid-range of the guidance was well-ahead of analysts estimate of $79.33M.
Net sales of Egrifta SV treatment to reduce excess abdominal fat in adult patients living with HIV and lipodystrophy were $11.42M vs. $10.34M a year earlier.
Sales from HIV drug, Trogarzo, were $7.85M vs. $7.44M, a year earlier.
The company said there were early signs of efficacy observed in the dose escalation portion of its Phase 1 study to treat cancers.
The company said the confirmed safety profile was at 300 mg/m2 or 1.5 times the therapeutic dose of chemotherapy drug, docetaxel, alone.
The company continued enrollment of clinical trial sites with 6 major cancer centers.
The pharmacokinetics data observed in humans showed low levels of free docetaxel, consistent with what was observed in the prior animal studies - THTX.
The trial showed the first patient achieved a confirmed partial response with the tumor mass reduction of 53%.